Darolutamide

Prostatic Neoplasms

BayerSmall moleculePhase 3Active

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 73/ 100

Competitive context

73 Active assets in the Prostatic Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Docetaxel Merck Sharp & Dohme LLC	Phase 4	BBB
PREDNISONE TABLETS Merck Sharp & Dohme LLC	Phase 3	BBB
Degarelix Novartis Pharmaceuticals	Phase 4	BBB
Abiraterone Acetate Qilu Pharmaceutical Co., Ltd.	Phase 3	BB
LEUPROLIDE Dana-Farber Cancer Institute	Phase 4	BB

View all 50 →

Same molecule, other indications

Darolutamide is also rated in:

castration-resistant prostate carcinomaDormant

BBB

Indicative ·

78 / 100

breast cancerDormant

BBB

Indicative ·

73 / 100

castration-resistant prostate carcinomaDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.